New hope for myelofibrosis: experimental combo targets Drug-Resistant patients
NCT ID NCT06887803
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether adding roginolisib to the standard drug ruxolitinib is safe and tolerable for adults with myelofibrosis whose disease no longer responds to JAK inhibitors. The study will enroll 26 participants and monitor side effects, heart changes, and lab results. If successful, this combination could become a new option for patients who have run out of effective treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
roginolisib (a PI3Kδ inhibitor) combined with ruxolitinib (a JAK inhibitor)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for myelofibrosis patients who have stopped responding to standard JAK inhibitor therapy.
What could go wrong
This is an early-phase trial with only 26 participants, so results may not apply to all patients. The combination may cause unexpected side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (MF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Avigunda Gran via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat
RECRUITINGBarcelona, 08908, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Azienda Ospedaliero Universitaria Careggi Firenze, Struttura Complessa di Ematologia
RECRUITINGFlorence, Florence, 50134, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Azienda Sanitario Universitaria Friuli Centrale
RECRUITINGUdine, 33100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Belfast City Hospital
RECRUITINGBelfast, BT9&AB, United Kingdom
Contact Email: •••••@•••••
-
Guy´s and St. Thomas NHS Foundation Trust
NOT_YET_RECRUITINGLondon, SE1 9RT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario de Salamanca
RECRUITINGSalamanca, 37007, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
IRCCS Clinical Institute Humanitas
RECRUITINGRozzano, Milan, 20089, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Istituto Romagnolo per lo Studio dei Tumori
RECRUITINGMeldola, 47014, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Istituto di Ematolgia e Oncologia Medica
RECRUITINGBologna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START Madrid CIOCC
RECRUITINGMadrid, 28050, Spain
Contact Email: •••••@•••••
-
United Lincolnshire Teach Hospitals NHS Trust, Pilgrim Hospital Boston
RECRUITINGBoston, Lincolnshire, PE21 9QS, United Kingdom
Contact Email: •••••@•••••
-
Vall d'Hebron University Hospital
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact